Hospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

2023

  1. Overview and update on molecular testing in non-small cell lung carcinoma utilizing endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples

    Diagnostic Cytopathology, Vol. 51, Núm. 1, pp. 26-35

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  2. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

    European urology oncology, Vol. 4, Núm. 3, pp. 502-505

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. EUS-guided tissue acquisition in the study of the adrenal glands: Results of a nationwide multicenter study

    PLoS ONE, Vol. 14, Núm. 6

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

2011

  1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653